critical limb ischemia therapeutics – pipeline assessment an

1. Critical Limb Ischemia Therapeutics - PipelineAssessment and Market Forecasts to 2017

2. The Critical Limb Ischemia Therapeutics Market is Forecast to Show Slow Growth until 2017 GlobalData estimates that the global critical limb ischemia therapeutics market was valued at $108.4m in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 2.4% over the next seven years, to reach $128.2m by 2017. This slow growth is primarily attributed to no FDA approved drug for CLI in the current market, biologics in the pipeline, low treatment seeking rate and awareness among the patients. The current competitive landscape consists of off label drugs. There are no trials being carried out on small molecules for CLI treatment. Entry of Biologics There is no approved therapy for the treatment of CLI. All the therapies in the pipeline are biologics, which indicates that the future treatment paradigm will be mainly driven by these therapies. These novel therapies are thus classified as first-in-class, and may offer good safety and efficacy for the disease. The unmet need of the CLI therapeutics market is high, and the entry of novel biologics in the market in coming years may fulfill this huge unmet need for the treatment of the disease. Slow Growth for the Critical Limb Ischemia Market GlobalData analysis shows that the CLI therapeutics pipeline is strong, with 14 therapies in various phases of clinical development. No approved therapy for CLI classifies the therapies under trials as firstin- class. The current pipeline has only biologics, with no small molecule and only one company sponsored trial in Phase

3. III. Phase II constitutes around 50% of the CLI pipeline, and their impact on the market will be on the later stage, leading to slow growth of the market until 2017. GlobalData, the industry analysis specialist, has released its new report, “Critical Limb Ischemia Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global critical limb ischemia market. The report identifies the key trends shaping and driving the global critical limb ischemia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global critical limb ischemia sector. This report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GlobalData’s team of industry experts. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Critical-Limb-Ischemia-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017

4. visit our report store: http://www.globaldata.com For more details contact: pressreleases@globaldata.com North America: +1 646 395 5477 Europe: +44 207 753 4299 +44 1204 543 533 Asia Pacific: +91 40 6616 6782